Results 71 to 80 of about 9,061 (176)

Abemaciclib [PDF]

Reactions Weekly, 2020
  +4 more sources

A probable case of cerebral amyloid angiopathy–related inflammation temporally associated with Abemaciclib: a Case Report

Case Reports in Oncology
Abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that has the ability to penetrate breast tissue and the blood-brain barrier, has been used as an addition to endocrine therapy in breast cancer.
Jacqueline AC Goos, Aarnout S. Plaisier, Astrid A. Van Gemeren   +2 more
doaj   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

MedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng, Zhipeng Shen, Yuanfang Wu, Xingze Huang, Zhongyuan Zhang, Jiangyu Liu, Qichun Wei, Wenhao Chen, Ye Chen, Liang Xu   +9 more
wiley   +1 more source

Abemaciclib-induced myocarditis in early breast cancer: a case report. [PDF]

BACKGROUND: Abemaciclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, is standard adjuvant therapy for hormone receptor (HR)-positive, HER2-negative early breast cancer.

core   +6 more sources

Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer [PDF]

Kaitlyn O’Keefe, Neelam V Desai, Antoinette R Tan Department of Solid Tumor and Investigational Therapeutics, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC, USACorrespondence: Antoinette R Tan, Department
Tan AR, O'Keefe K, Desai NV
core  

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

, 2018
The cyclinD:CDK4/6:Rb axis is dysregulated in a variety of human cancers. Targeting this pathway has proven to be a successful therapeutic approach in ER+ breast cancer.
Dylan Conklin, Ann Mc Nulty, Christophe Marchal, Erika von Euw, Neil O'Brien, Kevin Chau, Richard Beckmann, Ondrej Kalous, Dennis J. Slamon, Sara Hurvitz, Colleen Mockbee, Tong Luo, Josh Thomas   +12 more
core   +1 more source

Abemaciclib-associated kidney injuries: A retrospective analysis of the United States Food and Drug Administration adverse events reporting system

Journal of International Medical Research
Background Abemaciclib, an oral kinase inhibitor, is used to treat hormone receptor–positive and HER2-negative breast cancer patients. However, there has been a decrease in studies reporting adverse reactions to abemaciclib-related kidney injuries. Thus,
Xiangchun Xu, Xuzheng Guo, Jinhui Chen, Yuhua Pan, Jing Li, Jing Chen, Weihua Lai, Lu Lin   +7 more
doaj   +1 more source

Fecal metagenome and plasma metabolome analyses reveal changes in gut microbiota composition and plasma metabolites in rats with abemaciclib-induced diarrhea

BMC Gastroenterology
Abemaciclib-induced diarrhea is a common side effect of HR+/ HER2 − breast cancer treatment. The aim of this study was to explore changes in gut microbiota composition and plasma metabolites in rats with abemaciclib-induced diarrhea.
Ling Ye, Li Cao, Qiong Du, Rui Xu, Yu Han, Jiyong Liu   +5 more
doaj   +1 more source

Survival benefit from abemaciclib in non–small cell lung cancer by Kirsten rat sarcoma–mutation gene expression subtype: retrospective analysis from the JUNIPER Trial

Frontiers in Oncology
PurposeJUNIPER, a randomized, phase III trial of patients with stage IV non–small cell lung cancer and a detectable Kristen rat sarcoma (KRAS) mutation in codons 12 or 13 whose condition progressed after platinum-based chemotherapy and up to 1 additional
Jiangang Liu, Hong Wang, Amit Aggarwal, Maria Jesus Ortiz-Ruiz, Elisabet Zapatero-Solana, Maria Jose Lallena, Sandra Peregrina, Gloria Martinez del Hoyo, Susana Velasco, Philip J. Ebert, Xueqian Gong, Anwar M. Hossain, Shawn T. Estrem   +12 more
doaj   +1 more source

Pharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells

Frontiers in Oncology
IntroductionDiffuse pleural mesothelioma (DPM) of the pleura is a highly aggressive and treatment-resistant cancer linked to asbestos exposure. Despite multimodal treatment, the prognosis for DPM patients remains very poor, with an average survival of 2 ...
Aurora Costa, Iris Maria Forte, Francesca Pentimalli, Carmelina Antonella Iannuzzi, Luigi Alfano, Francesca Capone, Rosa Camerlingo, Alessandra Calabrese, Claudia von Arx, Reyes Benot Dominguez, Massimiliano Quintiliani, Michelino De Laurentiis, Andrea Morrione, Antonio Giordano, Antonio Giordano   +14 more
doaj   +1 more source